Phase II study of biweekly cetuximab and irinotecan as third-line therapy in patients with pre-treated KRAS exon2 wild-type metastatic colorectal c...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter H. Osumi
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors H. Osumi1, E. Shinozaki1, M. Suenaga1, S. Matsusaka1, I. Nakayama2, T. Wakatsuki3, M. Ogura4, M. Ozaka1, I. Takashi5, D. Takahari5, K. Chin1, N. Mizunuma1, K. Yamaguchi6
  • 1Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Japan, /
  • 2NTT Medical Center Tokyo, Shinagawa-ku, Japan, /
  • 3Cancer Institute Hospital Department of Gastroenterology, Koto-ku, Japan, /
  • 4Department of Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Japan, /
  • 5Cancer Institute Hospital, Koto-ku, Japan, /
  • 6Department of Gastroenterology Cancer Institute Hospital, Japanese Foundation for Cancer Research, Koto-ku, Japan, /

Abstract

Although there are several supported data that evaluated efficacy and safety about administering bi-weekly C-mab plus CPT-11 in European trials, there is a little data in Japan. The aim of this phase II study was to evaluate the efficacy, safety and to perform molecular analysis of C-mab and CPT-11 as third-line treatment in patients with pre-treated KRAS exon2 wild-type mCRC in Japan.